Remove

U.S. Patent and Trader Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of informal

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number			
iling Date		2006-05-19	
First Named Inventor Greg		ory Balfour JOHNSON	
Art Unit			
Examiner Name			
Mornov Docket Numb	nr .	102881-14-FE39215-06	

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	Date	Name of Pate of cited Docu	entee or Applicant ment	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	4509985	A	1985-04	4-09	Davidovits et al.		Cited in the application; whole document			
	2	5601643	A	1997-02	2-11	Silverstrim et al.		Cited in	Cited in the application		
	3	4640715	A	1987-02	2-03	Heitzmann et al.		Whole document			
If you wisi	If you wish to add additional U.S. Patent citation information please click the Add button.										
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	of cited Document		Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1										
If you wis	h to a	dd additional U.S. Publi		<u> </u>				d button			
	FOREIGN PATENT DOCUMENTS Remove										
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>			Publication Date	Name of Patentee or Applicant of cited Document		vhere Rel	or Relevant	тя
	1	2000/044685	wo		A	2000-08-03	Jin W.		See pages	7-21	

U.S.PATENTS

### Application Number Filing Date 2006-05-19 INFORMATION DISCLOSURE First Named Inventor Gregory Balfour JOHNSON STATEMENT BY APPLICANT Art I Init ( Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number 102881-14-FF39215-06

А

wo

1996-08-22

Drexel University [US]

Date Considered

By-Products Development Co. See pages 2-11, claim

					l		l	
	3	2003/078349	wo	A	2003-09-25	Kastanek F, & S, and Universitat fur Chemie und	Whole document	
	4	1989/005284	wo	A	1989-06-15	Lone Star Industries Inc.	Whole document	
	5	1993/016965	wo	A	1993-09-02	Pretoria Portland Cement Co. [ZA] * Gomersall J.E.	Whole document	
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner linitials* Cite initials* Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
	1 Copy of International Search Report dated December 17, 2004 for application PCT/AU/2004/01608							
	Copy of International Preliminary Report on Patentability dated December 13, 2005 for application PCT/ AU2004/001608							

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a 1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST 3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if

If you wish to add additional non-patent literature document citation information please click the Add button Add FXAMINER SIGNATURE

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

English language translation is attached

Examiner Signature

2 1996/025369

# Application Number Fing Date 2006-05-19 First Number Invalid Number Fing Date 2006-05-19 First Number Invalid Number Gregory Ballour JOHNSON Art Unit Examiner Name Inventor Invalid Number Invalid Numbe

## CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/1).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. Sea 7 CFR 1976(c)

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFP 1 97 and 1 98 to make the appropriate selection(s):

☐ None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew N. Parfomak/	Date (YYYY-MM-DD)	2006-05-19
Name/Print	Andrew N. Parfornak	Registration Number	32431

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.